Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Miami, FL
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
New Port Richey, FL
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Atlanta, GA
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Atlanta, GA
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Augusta, GA
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Sandy Springs, GA
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Sandy Springs, GA
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Chicago, IL
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Palos Heights, IL
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Palos Heights, IL
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Wichita, KA
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Marrero, LA
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Marrero, LA
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Canton, MI
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Canton, MI
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Detroit, MI
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Saginaw, MI
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Saginaw, MI
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Lincoln, NE
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Neptune, NJ
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Neptune, NJ
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Plainsboro, NJ
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Plainsboro, NJ
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
New York, NY
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Durham, NC
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Greensboro, NC
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Columbus, OH
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Dayton, OH
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Chattanooga, TN
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Seattle, WA
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Madison, WI
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
mi
from
Villach,
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
mi
from
Villach,
Click here to add this to my saved trials
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated:  12/6/2017
Clinical Research Facility
mi
from
Fort Myers, FL
Bay98-7196, Dose Finding / POC Study
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Enrolling
Updated: 12/6/2017
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Use of Nitric Oxide Metabolites for Predicting Embryo Quality in In-Vitro Fertilization (IVF)
Use of Nitric Oxide Metabolites for Predicting Embryo Quality in In-Vitro Fertilization
Status: Enrolling
Updated:  12/7/2017
Johns Hopkins Fertility Center
mi
from
Lutherville, MD
Use of Nitric Oxide Metabolites for Predicting Embryo Quality in In-Vitro Fertilization (IVF)
Use of Nitric Oxide Metabolites for Predicting Embryo Quality in In-Vitro Fertilization
Status: Enrolling
Updated: 12/7/2017
Johns Hopkins Fertility Center
mi
from
Lutherville, MD
Click here to add this to my saved trials
Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants < 33 Weeks
Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants <33 Weeks: A Randomized Controlled Trial
Status: Enrolling
Updated:  12/7/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants < 33 Weeks
Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants <33 Weeks: A Randomized Controlled Trial
Status: Enrolling
Updated: 12/7/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated:  12/7/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated: 12/7/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated:  12/7/2017
Children's Hospital Boston
mi
from
Boston, MA
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated: 12/7/2017
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated:  12/7/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
The Management of Postoperative Craniotomy Pain in Pediatric Patients
The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study
Status: Enrolling
Updated: 12/7/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Recombinant Human Prolactin for Lactation Induction
Recombinant Human Prolactin for Lactation Induction in Prolactin Deficient Mothers
Status: Enrolling
Updated:  12/8/2017
Massachusetts General Hospital
mi
from
Boston, MA
Recombinant Human Prolactin for Lactation Induction
Recombinant Human Prolactin for Lactation Induction in Prolactin Deficient Mothers
Status: Enrolling
Updated: 12/8/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Cervical Cancer Screening Project Part C
Minnesota Community Networks Center for Eliminating Cancer Disparities: Cervical Cancer Screening Project Part C Quantitative
Status: Enrolling
Updated:  12/8/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Cervical Cancer Screening Project Part C
Minnesota Community Networks Center for Eliminating Cancer Disparities: Cervical Cancer Screening Project Part C Quantitative
Status: Enrolling
Updated: 12/8/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Mind-body Intervention to Improve Body and/or Self Image
A Mind-body Intervention to Improve Body and/or Self Image: a Phase II Randomized Trial
Status: Enrolling
Updated:  12/10/2017
University of Michigan, School of Nursing
mi
from
Ann Arbor, MI
A Mind-body Intervention to Improve Body and/or Self Image
A Mind-body Intervention to Improve Body and/or Self Image: a Phase II Randomized Trial
Status: Enrolling
Updated: 12/10/2017
University of Michigan, School of Nursing
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed by Allopurinol in Adult Patients With Malignancy
Status: Enrolling
Updated:  12/11/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed by Allopurinol in Adult Patients With Malignancy
Status: Enrolling
Updated: 12/11/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
UC Davis Medical Center
mi
from
Sacramento, CA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Children's Hospital Colorado Center for Cancer and Blood Disorders
mi
from
Aurora, CO
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Children's Hospital Colorado Center for Cancer and Blood Disorders
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Child Neurology Center of Northwest Florida
mi
from
Gulf Breeze, FL
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Child Neurology Center of Northwest Florida
mi
from
Gulf Breeze, FL
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Rush University Medical Center
mi
from
Chicago, IL
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
University of Iowa
mi
from
Iowa City, IA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Boston Children's Hospital
mi
from
Boston, MA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research
mi
from
Saint Louis, MO
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials